Carryover Testing Challenged the Analytical Sequence, Not the Newborn’s Exposure History
The neonatal assay’s carryover assessment examined whether a preceding high-concentration sample could affect a later measurement. It addressed an instrument-process question, not a biological exposure pathway.
The protocol deliberately stressed the sequence
The investigators used samples at twice the upper quantification limit followed by low-range samples. They considered contamination associated with the syringe and the injection port, septum or column. This was a different question from whether cannabinoids were genuinely present in the original meconium or cord tissue.
Carryover differs from specimen contamination
Instrumental residue can transfer between analytical injections. Contamination before extraction, a mislabeled specimen or environmental exposure represents another problem requiring other safeguards. A carryover validation cannot independently rule out every alternative source of an unexpected result.
Application to a disputed batch needs its own records
The design shows how the researchers challenged one analytical vulnerability. It does not prove that every future run or another laboratory’s sequence is unaffected. Assess the actual sequence, blank or control behavior, cleaning procedures and reported analyte before attributing a low signal to carryover. Conversely, simply invoking carryover without supporting batch evidence does not invalidate a positive result. The validation’s scope is analytical reliability, rather than a reconstruction of prenatal dose, timing or harm.
Related analysis: the study’s broader findings and limitations.
